Psyence Biomedical Ltd. (Nasdaq: PBM) announced that its strategic partner PsyLabs has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract that met all microbial safety standards for food-grade consumption, as verified by an accredited third-party laboratory. This milestone represents a significant advancement in the production of high-purity psychedelic active pharmaceutical ingredients (APIs).
The achievement reflects the impact of Psyence BioMed's ongoing investment and collaboration with PsyLabs, which began in 2024 when the company acquired an equity stake in the psychedelic compound producer and continued the investment in 2025. The partnership supports PsyLabs' development of scalable, compliant, and globally relevant psychedelic APIs.
Manufacturing Excellence and Quality Standards
PsyLabs operates from an ISO 22000-certified facility audited by the British Standards Institution, ensuring the highest standards of safety and traceability. The company is federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets.
"This is a groundbreaking moment for our entire team on the ground who have put countless hours and effort into ensuring our naturally derived, sustainable input materials are extracted with the same caution, mindfulness, and care, all covering the GMP manufacturing processes," said Cody Robyn Futeran, Head of Extraction Innovations and Business Development at PsyLabs.
Tony Budden, CEO of PsyLabs, emphasized the broader significance of the achievement: "Achieving this milestone is a testament to our team's dedication and our state-of-the-art facilities. We are committed to refining our processes to achieve even higher purity levels, supporting the growing demand for high-quality psychedelic APIs."
Expanding Production Capabilities
PsyLabs continues to push the boundaries of pharmaceutical innovation, with ongoing development aimed at further increasing purity levels to isolate standards. The company's extraction division is currently expanding its chemistry production area to ensure it consistently meets the growing demand for Ibogaine HCL, Psilocybin Isolate, and other 90% purity SKUs, derived from both Iboga and Mushrooms.
The newly produced Ibogaine will be available to licensed research institutions and developers worldwide, ensuring a reliable and ethically sourced supply. PsyLabs has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.
Strategic Partnership Impact
Psyence BioMed positions itself as one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. The company is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq.
The partnership with PsyLabs aligns with Psyence BioMed's commitment to addressing unmet mental health needs, particularly in palliative care, through an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.
PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics, with a focus on natural compound purification, regulatory support, and global distribution capabilities.
